<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363952">
  <stage>Registered</stage>
  <submitdate>31/03/2013</submitdate>
  <approvaldate>9/04/2013</approvaldate>
  <actrnumber>ACTRN12613000378729</actrnumber>
  <trial_identification>
    <studytitle>Is Dexmedetomidine protective from postoperative cognitive dysfunction in elderly patients after prolonged surgical anesthesia? </studytitle>
    <scientifictitle>Is Dexmedetomidine protective from postoperative cognitive dysfunction in elderly patients after prolonged surgical anesthesia? </scientifictitle>
    <utrn>U1111-1141-2493</utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>prolonged lower abdominal surgery</healthcondition>
    <healthcondition>postoperative cognitive dysfunction</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Group (D) Dexmeditomedine : will receive sevoflurane inhalation,fentanyl 100 mic, Rocronium 50 mg.and Dexmeditomedine infusion (0.4 mic/kg/hour)continous infusion from the start of the surgery till skin closure.

Group (s) Sevoflorane (or the control group) will receive sevoflurane inhalation,fentany100 mic.l, Rocronium 50 mg and Saline infusion .

 For both groups,  Neurocognetive tests (Montreal Cognetive Assessment and Stroop color word interference tests) will be done the night before the surgery and will be repeated 24 hours postoperatively</interventions>
    <comparator>Group (s) Sevoflorane (or the control group) will receive sevoflurane inhalation,fentany100 mic., Rocronium 50 mg and Saline infusion (0.4 mic/kg/hr)
continous infusion from the start of the surgery till skin closure.

</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Measure the change between preoperative and postoperative cognitive function using Montreal Cognitive Assessment and Stroop color word interference tests .</outcome>
      <timepoint> 24 hours postoperative</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>60 years old or above, bothe sexes without any neuropsychatric disorder, Scheduled for prolonged (two hours or more) abdominal surgery</inclusivecriteria>
    <inclusiveminage>60</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with any psychological or neurological  disorder,or with preexisting cognitive dysfunction.
patients with cardiac disease
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be randomly allocated using computer generated
numbers. Allocation will beconcealed using
opaque sealed envelopes that will be opened just prior
to induction of general anaesthesia</concealment>
    <sequence>randomization will be done using a randomisation table created by computer software </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>uncorrected Chi-Square statistic test will be used to evaluate the null hypothesis
T test, Repeated T test, correlation,Regression test
Other statistical methods may be added according to the data collected at the end of the study.
Sample size: we hypothesize that Dexmedetomidine can reduce postoperative cognitive disorder by 20%or more.the calculated sample size of 30 patients was in order to be able to reject the null hypothesis that the incidence of postoperative cognitive disorder in both groups is equal with the power of 80%and 0.05 level of significance</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>10/05/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>ahmad ramzy</primarysponsorname>
    <primarysponsoraddress>King Faisal Specialist Hospital and research center,Anesthesia department,MBC J22
Rawda street, pobox 40047.Jeddah 21499, Saudi Arabia</primarysponsoraddress>
    <primarysponsorcountry>Saudi Arabia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>30 patients, above 60 years old of both sex who will be scheduled for elective abdominal surgery under general anesthesiafor more than two hours will be selected to participate in this study, Patients will be randomized into 2 groups (15 patients in each group)
Group (D) Dexmeditomedine : will receive sevoflurane inhalation,fentanyl, Rocronium and Dexmeditomedine infusion (0.4 mic/kg/hour)

Group (s) Sevoflorane (or the control group) will receive sevoflurane inhalation,fentanyl, Rocronium and Saline infusion .

 For both groups,  Neurocognetive tests (Montreal Cognetive Assessment and Stroop color word interference tests) will be done the night before the surgery and will be repeated 24 hours postoperatively</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>institutional review board,King Faisal specialist hospital.Jeddah</ethicname>
      <ethicaddress>King Faisal Specialist Hospital and research center,Anesthesia department,MBC J22
Rawda street, pobox 40047.Jeddah 21499, Saudi Arabia</ethicaddress>
      <ethicapprovaldate>18/04/2010</ethicapprovaldate>
      <hrec>2010/08</hrec>
      <ethicsubmitdate>7/03/2010</ethicsubmitdate>
      <ethiccountry>Saudi Arabia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Ahmad Ramzy</name>
      <address>King Faisal Specialist Hospital and research center,Anesthesia department,MBC J22 Rawda street, pobox 40047.Jeddah 21499, Saudi Arabia</address>
      <phone>+966534409797</phone>
      <fax />
      <email>ahmed_ramzy73@hotmail.com</email>
      <country>Saudi Arabia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ahmad Ramzy</name>
      <address>King Faisal Specialist Hospital and research center,Anesthesia department,MBC J22 Rawda street, pobox 40047.Jeddah 21499, Saudi Arabia</address>
      <phone>+966534409797</phone>
      <fax />
      <email>ahmed_ramzy73@hotmail.com</email>
      <country>Saudi Arabia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ahmad Ramzy</name>
      <address>King Faisal Specialist Hospital and research center,Anesthesia department,MBC J22 Rawda street, pobox 40047.Jeddah 21499, Saudi Arabia</address>
      <phone>+966534409797</phone>
      <fax />
      <email>ahmed_ramzy73@hotmail.com</email>
      <country>Saudi Arabia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ahmad ramzy</name>
      <address>King Faisal Specialist Hospital and research center,Anesthesia department,MBC J22 Rawda street, pobox 40047.Jeddah 21499, Saudi Arabia</address>
      <phone>00966534409797</phone>
      <fax />
      <email>ahmed_ramzy73@hotmail.com</email>
      <country>Saudi Arabia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>